Company intelligence

NUVL

Nuvalent, Inc. · NASDAQ · Healthcare

Price$123.96+0.00% · +$0.00

Market cap9.13BEquity value

P / E-21.8Trailing ratio

Volume0Latest session

Market data

NUVL price chart

TradingView

Related signals

1 min delayed

Browse public NUVL signals with their source context and measured market impact. Open any signal for its permanent analysis page.

NUVLNov 17, 2025-6.04% since signal

Nuvalent Reports 31% Response Rate In Patients With Advanced Form Of Lung Cancer

Topline ALKOVE-1 data: recommended Phase 2 dose 150 mg once daily. TKI‑pretreated cohort (n=253) showed 31% ORR; median DOR not reached. TKI‑naïve exploratory cohort (n=44) reported 86% ORR and 9% CR. Strong intracranial activity: IC‑ORR 78%, IC‑CR 44%, no CNS progression. Nuvalent plans pre‑NDA meeting; NUVL stock jumped ~16% on results.

View signal analysis

Research